A Review on the Association between Dyslipidemia, Glucose Tolerance, and Coronary Heart Disease Risk

© 2026 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

As one of the main chronic diseases in modern society, coronary heart disease, as a major disease that affects people’s lives and health, has the characteristics of hidden onset and sudden onset. Coronary heart disease has relatively clear risk factors. Among them, blood lipid levels and blood sugar levels, as two main risk factors, play an important role in promoting the onset of coronary heart disease. The two complement each other in a vicious cycle, synergize and promote each other, promote the process of coronary atherosclerosis, thereby causing coronary heart disease. Multiple components in blood lipids and poor management of long-term blood sugar levels play a major role in specific clinical problems. This article reviews the different components of blood lipids and the effects of hyperglycemia on coronary heart disease, and initially expounds the mechanism by which blood lipids and blood sugar levels synergize each other to aggravate the risk of coronary heart disease, and combines them with relevant clinical issues, in order to help clinicians guide the prevention of coronary heart disease in terms of blood lipids and blood sugar levels.

References

Xu S, Scott C, Coleman R, et al., 2021, Predicting the Risk of Developing Type 2 Diabetes in Chinese People Who Have Coronary Heart Disease and Impaired Glucose Tolerance. Journal of Diabetes, 13(10): 817–826.

Cao L, Wang P, Luan H, et al., 2020, Elevated 1-H Postload Plasma Glucose Levels Identify Coronary Heart Disease Patients with Greater Severity of Coronary Artery Lesions and Higher Risk of 1-Year Re-Admission. Diabetes & Vascular Disease Research, 17(1): 1479164119896978.

Welten S, van der Heijden A, Remmelzwaal S, et al., 2023, Prolongation of the QTc Interval Is Associated with an Increased Risk of Cardiovascular Diseases: The Hoorn Study. Journal of Electrocardiology, 80: 133–138.

Cai X, Zhang Y, Li M, et al., 2020, Association Between Prediabetes and Risk of All-Cause Mortality and Cardiovascular Disease: Updated Meta-Analysis. BMJ, 370: m2297.

Tsuchida K, Mitsuma W, Sato Y, et al., 2020, Impaired Glucose Tolerance and Future Cardiovascular Risk After Coronary Revascularization: A 10-Year Follow-Up Report. Acta Diabetologica, 57(2): 173–182.

Wang B, Zhang H, Sun Y, et al., 2023, Association of Sleep Patterns and Cardiovascular Disease Risk Is Modified by Glucose Tolerance Status. Diabetes/Metabolism Research and Reviews, 39(6): e3642.

Visco V, Forte M, Giallauria F, et al., 2025, Epigenetic Mechanisms Underlying the Beneficial Effects of Cardiac Rehabilitation: An Overview From the Working Groups of “Cellular and Molecular Biology of the Heart” and “Cardiac Rehabilitation and Cardiovascular Prevention” of the Italian Society of Cardiology (SIC). International Journal of Cardiology, 429: 133166.

Pradhan A, Bhandari M, Vishwakarma P, et al., 2023, Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol. Journal of Cardiovascular Development and Disease, 10(5): 195.

Amarenco P, Kim J, Labreuche J, et al., 2020, Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke. Stroke, 51(4): 1231–1239.

Tan M, Yang S, Xu X, 2023, High-Density Lipoprotein Cholesterol and Carcinogenesis. Trends in Endocrinology and Metabolism, 34(5): 303–313.

Hayes M, 2024, Non-Insulin Medications for the Management of Type 2 Diabetes. Home Healthcare Now, 42(2): 72–77.

Zachariah G, 2023, Management of Triglycerides, Non-High Density Lipoprotein Cholesterol and High Density Lipoprotein Cholesterol. Indian Heart Journal, 76(Suppl 1): S58–S64.

Xiang Q, Tian F, Xu J, et al., 2022, New Insight Into Dyslipidemia-Induced Cellular Senescence in Atherosclerosis. Biological Reviews, 97(5): 1844–1867.

Wu T, Chou C, Liu C, et al., 2025, Lipid Profiles and Their Association With Incident Carotid Atherosclerosis: A Community-Based Prospective Study in Taiwan. Nutrition, Metabolism and Cardiovascular Diseases, 35(6): 104023.

Fukami H, Oike Y, 2025, ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 32(9): 1071–1078.

Xing L, Liu Y, Wang J, et al., 2023, High-Density Lipoprotein and Heart Failure. Reviews in Cardiovascular Medicine, 24(11): 321.

Razavi A, Jain V, Grandhi G, et al., 2024, Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease? Journal of Clinical Endocrinology & Metabolism, 109(2): 321–332.

Piccoli R, Simões W, Custódio S, et al., 2024, Sustainable Intervention: Grape Pomace Flour Ameliorates Fasting Glucose and Mitigates Streptozotocin-Induced Pancreatic Damage in a Type 2 Diabetes Animal Model. Pharmaceuticals, 17(11): 1530.

Jose J, Madhu L, Bhongir A, et al., 2024, Evaluating Dyslipidemia and Atherogenic Indices as Predictors of Coronary Artery Disease Risk: A Retrospective Cross-Sectional Study. Cureus, 16(10): e71187.

Najafipour H, Yousefzadeh G, Baneshi M, et al., 2021, Prevalence and 5-Year Incidence Rate of Dyslipidemia and Its Association With Other Coronary Artery Disease Risk Factors in Iran: Results of the Kerman Coronary Artery Disease Risk Factors Study (Phase 2). Journal of Research in Medical Sciences, 26: 99.

Arvanitis M, Lowenstein C, 2023, Dyslipidemia. Annals of Internal Medicine, 176(6): ITC81–ITC96.

Alhroub W, Jabareen M, Abu-Mayyaleh H, et al., 2025, Severe Left Main Coronary Artery Disease and STEMI in a 19-Year-Old Without Traditional Risk Factors: A Rare Case of Premature Coronary Artery Disease. SAGE Open Medical Case Reports, 13: 2050313X251321041.

Wei Y, Xu W, 2019, Effect of Acarbose on Cardiovascular Events and New-Onset Diabetes in Patients With Coronary Heart Disease and Impaired Glucose Tolerance. Future Cardiology, 15(2): 127–133.

de la Cruz-Ares S, Gutiérrez-Mariscal F, Alcalá-Díaz J, et al., 2021, Quality and Quantity of Protein Intake Influence Incidence of Type 2 Diabetes Mellitus in Coronary Heart Disease Patients: From the CORDIOPREV Study. Nutrients, 13(4): 1217.

Zhan Q, Xie L, Wang C, 2023, Promoting Critical Care System and Capacity Building in Pulmonary and Critical Care Medicine Subspecialties. Zhonghua Yi Xue Za Zhi, 103(40): 3149–3151.

Alshehri A, Guan D, Li P, et al., 2024, Trends in Utilization Patterns of Newer Glucose-Lowering Drugs in US Adults With Type 2 Diabetes and a History of Coronary Heart Disease or Heart Failure: 2005–2019. Primary Care Diabetes, 18(5): 561–563.

Kumar S, Talwalkar P, Das S, et al., 2019, Cardiovascular Effects of Sodium Glucose Co-Transporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Indian Journal of Endocrinology and Metabolism, 23(1): 150–158.

Vellapandian C, 2024, Exploring the Long-Term Effect of Artificial Sweeteners on Metabolic Health. Cureus, 16(9): e70043.

Previous article in this issue

Next article in this issue